We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
- Authors
Sugidachi, A; Ogawa, T; Kurihara, A; Hagihara, K; Jakubowski, J A; Hashimoto, M; Niitsu, Y; Asai, F
- Abstract
Prasugrel is a novel orally active thienopyridine prodrug with potent and long-lasting antiplatelet effects. Platelet inhibition reflects inhibition of P2Y(12) receptors by its active metabolite (AM). Previous studies have shown that the antiplatelet potency of prasugrel is at least 10 times higher than that of clopidogrel in rats and humans, but the mechanism of its higher potency has not yet been fully elucidated.
- Publication
Journal of thrombosis and haemostasis : JTH, 2007, Vol 5, Issue 7, p1545
- ISSN
1538-7933
- Publication type
Journal Article
- DOI
10.1111/j.1538-7836.2007.02598.x